{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:36:01Z","timestamp":1770741361952,"version":"3.49.0"},"reference-count":45,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. Various pretreatment biomarkers might affect biochemical response to fg-SRLs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To identify clinical predictors of the biochemical response to fg-SRLs monotherapy defined as biochemical response (insulin-like growth factor (IGF)-1\u2005\u2264\u20051.3\u2005\u00d7\u2005ULN (upper limit of normal)), partial response (&amp;gt;20% relative IGF-1 reduction without normalization), and nonresponse (\u226420% relative IGF-1 reduction), and IGF-1 reduction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective multicenter study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Eight participating European centers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a meta-analysis of participant data from 2 cohorts (Rotterdam and Li\u00e8ge acromegaly survey, 622 out of 3520 patients). Multivariable regression models were used to identify predictors of biochemical response to fg-SRL monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Lower IGF-1 concentration at baseline (odds ratio (OR)\u2005=\u20050.82, 95% confidence interval (CI) 0.72\u20130.95 IGF-1 ULN, P\u2005=\u2005.0073) and lower bodyweight (OR\u2005=\u20050.99, 95% CI 0.98\u20130.99 kg, P\u2005=\u2005.038) were associated with biochemical response. Higher IGF-1 concentration at baseline (OR\u2005=\u20051.40, (1.19\u20131.65) IGF-1 ULN, P\u2005\u2264\u2005.0001), the presence of type 2 diabetes (oral medication OR\u2005=\u20052.48, (1.43\u20134.29), P\u2005=\u2005.0013; insulin therapy OR\u2005=\u20052.65, (1.02\u20136.70), P\u2005=\u2005.045), and higher bodyweight (OR\u2005=\u20051.02, (1.01\u20131.04) kg, P\u2005=\u2005.0023) were associated with achieving partial response. Younger patients at diagnosis are more likely to achieve nonresponse (OR\u2005=\u20050.96, (0.94\u20130.99) year, P\u2005=\u2005.0070). Baseline IGF-1 and growth hormone concentration at diagnosis were associated with absolute IGF-1 reduction (\u03b2\u2005=\u20050.90, standard error (SE)\u2005=\u20050.02, P\u2005\u2264\u2005.0001 and \u03b2 \u2005=\u20050.002, SE\u2005=\u20050.001, P\u2005=\u2005.014, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Baseline IGF-1 concentration was the best predictor of biochemical response to fg-SRL, followed by bodyweight, while younger patients were more likely to achieve nonresponse.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa387","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T06:48:24Z","timestamp":1593240504000},"page":"2964-2974","source":"Crossref","is-referenced-by-count":40,"title":["Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly"],"prefix":"10.1210","volume":"105","author":[{"given":"Eva C","family":"Coopmans","sequence":"first","affiliation":[{"name":"Department of Medicine, Endocrinology section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands"}]},{"given":"Tim I M","family":"Korevaar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands"}]},{"given":"Sebastiaan W F","family":"van Meyel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands"}]},{"given":"Adrian F","family":"Daly","sequence":"additional","affiliation":[{"name":"Endocrinologie Centre Hospitalier Universitaire de Li\u00e8ge, Domaine Universitaire du Sart-Tilman, Li\u00e8ge, Belgium"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital de Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse, Le Kremlin Bic\u00eatre, France"},{"name":"Universit\u00e9 Paris-Saclay, Univ. Paris-Sud, Inserm, Signalisation Hormonale, Physiopathologie Endocrinienne et M\u00e9tabolique, Le Kremlin-Bic\u00eatre, France"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[{"name":"Aix-Marseille Universit\u00e9, CNRS, Marseille, France"},{"name":"APHM, H\u00f4pital Conception, Service d\u2019Endocrinologie, Diab\u00e8te et Maladies M\u00e9taboliques, Centre de R\u00e9f\u00e9rence des Maladies Rares d\u2019Origine Hypophysaire, Marseille, France"}]},{"given":"Brigitte","family":"Delemer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Nutrition, University Hospital of Reims, Reims, France"}]},{"suffix":"Jr.","given":"V\u00e1clav","family":"H\u00e1na","sequence":"additional","affiliation":[{"name":"3rd Department of Internal Medicine, First Medical Faculty, Charles University, Prague, Czech Republic"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Clinica e Chirurgia, Universit\u00e0 Federico II di Napoli, Naples, Italy"}]},{"given":"Davide","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism Section and Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Centro Hospitalar S. Jo\u00e3o, Porto, Portugal"}]},{"given":"Marie-Lise","family":"Jaffrain-Rea","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, L\u2019Aquila and Neuromed, IRCCS, Pozzilli, Italy"}]},{"given":"G\u00fcnter K","family":"Stalla","sequence":"additional","affiliation":[{"name":"Clinical Neuroendocrinology, Max-Planck-Institute of Psychiatry, Munich, Germany"}]},{"given":"Carmen","family":"Fajardo-Monta\u00f1ana","sequence":"additional","affiliation":[{"name":"Servicio de Endocrinolog\u00eda, Hospital Universitario La Ribera, Valencia, Spain"}]},{"given":"Albert","family":"Beckers","sequence":"additional","affiliation":[{"name":"Endocrinologie Centre Hospitalier Universitaire de Li\u00e8ge, Domaine Universitaire du Sart-Tilman, Li\u00e8ge, Belgium"}]},{"given":"Aart J","family":"van der Lely","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands"}]},{"given":"Patrick","family":"Petrossians","sequence":"additional","affiliation":[{"name":"Endocrinologie Centre Hospitalier Universitaire de Li\u00e8ge, Domaine Universitaire du Sart-Tilman, Li\u00e8ge, Belgium"}]},{"given":"Sebastian J C M M","family":"Neggers","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands"}]}],"member":"80","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"issue":"11","key":"2021122202413997700_CIT0001","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2021122202413997700_CIT0002","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol."},{"issue":"1","key":"2021122202413997700_CIT0003","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev."},{"issue":"3","key":"2021122202413997700_CIT0004","doi-asserted-by":"crossref","first-page":"R223","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J Mol Endocrinol."},{"issue":"3","key":"2021122202413997700_CIT0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol."},{"issue":"8","key":"2021122202413997700_CIT0006","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","article-title":"A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly","volume":"93","author":"Murray","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122202413997700_CIT0007","article-title":"Tumor responses to lanreotide autogel\/depot 120 mg after 12 and 24 weeks are correlated with tumor responses after 48 weeks in treatment-na\u00efve acromegalic patients: post hoc analyses of the PRIMARYS study","volume":"35","author":"Caron","year":"2014","journal-title":"Endocr Rev."},{"issue":"1","key":"2021122202413997700_CIT0008","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary."},{"issue":"3","key":"2021122202413997700_CIT0009","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122202413997700_CIT0010","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest."},{"issue":"1","key":"2021122202413997700_CIT0011","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122202413997700_CIT0012","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-18-0015","article-title":"Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study","volume":"178","author":"Esposito","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2021122202413997700_CIT0013","article-title":"Body mass index as one of determinants of biochemical control in acromegaly: 2-year data from the soda registry","volume":"38","author":"Gordon","year":"2017","journal-title":"Endocr Rev."},{"issue":"5","key":"2021122202413997700_CIT0014","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab."},{"issue":"5","key":"2021122202413997700_CIT0015","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One."},{"issue":"4","key":"2021122202413997700_CIT0016","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1210\/jc.2008-1420","article-title":"Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues","volume":"94","author":"Sherlock","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122202413997700_CIT0017","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","article-title":"Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti","year":"2010","journal-title":"Pituitary."},{"issue":"2","key":"2021122202413997700_CIT0018","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2265.1992.tb02304.x","article-title":"The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex","volume":"37","author":"van der Lely","year":"1992","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"8","key":"2021122202413997700_CIT0019","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis","volume":"90","author":"Freda","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122202413997700_CIT0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.1.01824","article-title":"Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs","volume":"152","author":"Petrossians","year":"2005","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2021122202413997700_CIT0021","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ando.2012.05.001","article-title":"The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly","volume":"73","author":"Petrossians","year":"2012","journal-title":"Ann Endocrinol (Paris)."},{"issue":"3","key":"2021122202413997700_CIT0022","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary."},{"issue":"6","key":"2021122202413997700_CIT0023","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF03343583","article-title":"Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide","volume":"22","author":"Suliman","year":"1999","journal-title":"J Endocrinol Invest."},{"issue":"11","key":"2021122202413997700_CIT0024","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer."},{"issue":"11","key":"2021122202413997700_CIT0025","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021122202413997700_CIT0026","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41574-018-0114-1","article-title":"The causes and consequences of pituitary gigantism","volume":"14","author":"Beckers","year":"2018","journal-title":"Nat Rev Endocrinol."},{"issue":"2","key":"2021122202413997700_CIT0027","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev."},{"issue":"10","key":"2021122202413997700_CIT0028","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2021122202413997700_CIT0029","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1530\/EJE-16-0956","article-title":"A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues","volume":"176","author":"Franck","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2021122202413997700_CIT0030","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122202413997700_CIT0031","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122202413997700_CIT0032","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jcmm.13440","article-title":"Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly","volume":"22","author":"Venegas-Moreno","year":"2018","journal-title":"J Cell Mol Med."},{"issue":"1","key":"2021122202413997700_CIT0033","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest."},{"key":"2021122202413997700_CIT0034","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","author":"Coopmans","journal-title":"Figshare Repository"},{"issue":"9","key":"2021122202413997700_CIT0035","first-page":"2768","article-title":"Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients\u2013a clinical research center study","volume":"80","author":"Newman","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122202413997700_CIT0036","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-10-1050","article-title":"Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry","volume":"164","author":"Fieffe","year":"2011","journal-title":"Eur J Endocrinol."},{"issue":"12","key":"2021122202413997700_CIT0037","first-page":"4712","article-title":"Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation","volume":"85","author":"Leung","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122202413997700_CIT0038","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1210\/jc.2012-2896","article-title":"The metabolic profile in active acromegaly is gender-specific","volume":"98","author":"Ciresi","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122202413997700_CIT0039","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00002512-200017020-00001","article-title":"Pharmacotherapy or surgery as primary treatment for acromegaly?","volume":"17","author":"Ferone","year":"2000","journal-title":"Drugs Aging."},{"issue":"6","key":"2021122202413997700_CIT0040","first-page":"2779","article-title":"Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122202413997700_CIT0041","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/edrv-4-3-271","article-title":"Pathophysiology of acromegaly","volume":"4","author":"Melmed","year":"1983","journal-title":"Endocr Rev."},{"issue":"2","key":"2021122202413997700_CIT0042","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.01968","article-title":"Predictors and rates of treatment-resistant tumor growth in acromegaly","volume":"153","author":"Besser","year":"2005","journal-title":"Eur J Endocrinol."},{"issue":"10","key":"2021122202413997700_CIT0043","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1210\/jc.2001-012012","article-title":"Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size","volume":"87","author":"Bevan","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122202413997700_CIT0044","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1210\/jc.2005-1208","article-title":"Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122202413997700_CIT0045","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa387\/33433628\/dgaa387.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/9\/2964\/41847281\/dgaa387.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/9\/2964\/41847281\/dgaa387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T02:42:37Z","timestamp":1640140957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/9\/2964\/5863389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,26]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa387","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,6,26]]}}}